Lore Gruenbaum is a biochemist and molecular biologist with 15 years of experience in drug discovery and clinical development of small and large molecules as well as diagnostics and personalized health care approaches. Lore was most recently employed as the Director of Biomarker Strategy, Infectious Diseases at the Roche Translational Clinical Research Center in New York City where she was responsible for drug target and biomarker identification, preclinical and clinical biomarker studies and experimental medicine studies. Lore obtained her doctorate in Biochemistry with ‘Summa cum Laude’ from the Free University of Berlin and completed her postdoctoral training in Neuroscience at Yale University in the laboratories of Prof. Tom Carew and Prof. Marina Picciotto.
Lore spent nine years as a discovery group leader at Boehringer Ingelheim Pharmaceuticals, CT. In 2008, Lore took a new role as the Leader of the Early Safety Group and implemented predictive cytotoxicity screening for the characterization and prioritization of lead compounds. Two years later, she became the Leader of the High-Content Biology Group responsible for the discovery of biomarkers and for pathway analysis to support target identification and validation.
In September 2010, Lore joined Roche Pharma as the Head of Biomarker and Pathway Analysis for Virology. In 2011, Lore became the leader of the Roche systems biology initiative, organized and led two scientific advisory boards on systems biology in Europe and North America and developed a global strategy for the implementation of systems biology modeling at Roche. In 2012 she accepted her last position in the expanding Infectious Disease department at Roche.